SEPTIN9 and colorectal carcinoma: Based on circulating methylated SEPT9 DNA for detecting CRC in a study by Church et al., the methylation of SEPT9 DNA had a sensitivity of 35.0% for patients with stage I CRC, 63% for stage II, 46.0% for stage III, and 77.4% for stage IV, with a specificity of 91.5% (47).